Free shipping on all orders over $ 500

Avexitide (Exendin 9-39)

Cat. No. M10089
Avexitide (Exendin 9-39) Structure

Exendin Fragment 9-39; Exendin-3 (9-39) amide

Size Price Availability Quantity
1mg USD 216  USD240 In stock
5mg USD 639  USD710 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Avexitide (Exendin 9-39) is an antagonist of glucagon-like peptide-1 (GLP-1) receptor, and also acts as an inhibitor of glucosedependent insulinotropic polypeptide (GIP)-receptor binding. Avexitide (Exendin 9-39) is a competitive inhibitor of exendin-3 and exendin-4. It also prevents the production of cAMP by GIP. GLP-1, along with GIP, acts as a physiological incretin. Avexitide (Exendin 9-39) has been used to study its effect on basal microvascular permeability.

Amino Acid Sequence


Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 3369.76
Formula C149H234N40O47S
CAS Number 133514-43-9
Purity >99%
Solubility Water 30 mg/mL
Storage -20°C, dry, sealed

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Kristopher C Dozier, et al. Peptides. 2009 Sep;30(9):1735-41. PMID: 19560500.

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
V A Gault, et al. Diabetologia. 2003 Feb;46(2):222-30. PMID: 12627321.

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39
C M Edwards, et al. Diabetes. 1999 Jan;48(1):86-93. PMID: 9892226.

Related Glucagon Receptor Products

PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R) agonist.


Teduglutide is a glucagon-like peptide-2 (GLP- 2) receptor agonist used for the treatment of short-bowel syndrome.


NNC0640 is a potent, negative allosteric modulator (NAM) of human G-protein-coupled glucagon receptor (GCGR) with IC50 of 69.2 nM.

Cotadutide acetate

Cotadutide acetate is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor, with EC50 values of 6.9 pM and 10.2 pM, respectively.

Tirzepatide TFA

Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Abmole Inhibitor Catalog 2017

Keywords: Avexitide (Exendin 9-39), Exendin Fragment 9-39; Exendin-3 (9-39) amide supplier, Glucagon Receptor, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.